Adam L Halberstadt1,2, Natalia Slepak3, James Hyun4, Mahalah R Buell4, Susan B Powell4,5. 1. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, 92093-0804, La Jolla, CA, USA. ahalbers@ucsd.edu. 2. Research Service, VA San Diego Healthcare System, San Diego, CA, USA. ahalbers@ucsd.edu. 3. Department of Biology, University of California San Diego, La Jolla, CA, USA. 4. Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, 92093-0804, La Jolla, CA, USA. 5. Research Service, VA San Diego Healthcare System, San Diego, CA, USA.
Abstract
RATIONALE: Methoxetamine (MXE) is a ketamine analog sold online that has been subject to widespread abuse for its dissociative and hallucinogenic effects. Previous studies have shown that MXE has high affinity for the phencyclidine (PCP) binding site located within the channel pore of the NMDA receptor (NMDAR), but little is known about its behavioral effects. Dissociative anesthetics such as ketamine and PCP produce a characteristic behavioral profile in rats that includes locomotor hyperactivity and disruption of prepulse inhibition (PPI) of acoustic startle. METHODS: The goal of the present investigation was to determine whether MXE produces PCP-like effects in Sprague-Dawley rats using the PPI paradigm and the behavioral pattern monitor (BPM), which enables analyses of patterns of locomotor activity and investigatory behavior. PPI studies were conducted with several other uncompetitive NMDAR antagonists that produce dissociative effects in humans, including PCP, the S-(+) and R-(-) isomers of ketamine, and N-allylnormetazocine (NANM; SKF-10,047). RESULTS: MXE disrupted PPI when administered at 3 and 10 mg/kg SC. The rank order of potency of MXE and the other test compounds in the PPI paradigm (PCP > MXE > S-(+)-ketamine > NANM > R-(-)-ketamine) parallels their affinities for the PCP binding site reported in the literature. When tested in the BPM, 10 mg/kg MXE induced locomotor hyperactivity, reduced the number of rearings, increased the roughness of locomotor paths, and produced perseverative patterns of locomotion. Administration of PCP (2.25 and 6.75 mg/kg, SC) produced a similar profile of effects in the BPM. CONCLUSIONS: These results indicate that MXE produces a behavioral profile similar to that of other psychotomimetic uncompetitive NMDAR antagonists. Our findings support the classification of MXE as a dissociative drug and suggest that it likely has effects and abuse potential similar to that of PCP and ketamine.
RATIONALE: Methoxetamine (MXE) is a ketamine analog sold online that has been subject to widespread abuse for its dissociative and hallucinogenic effects. Previous studies have shown that MXE has high affinity for the phencyclidine (PCP) binding site located within the channel pore of the NMDA receptor (NMDAR), but little is known about its behavioral effects. Dissociative anesthetics such as ketamine and PCP produce a characteristic behavioral profile in rats that includes locomotor hyperactivity and disruption of prepulse inhibition (PPI) of acoustic startle. METHODS: The goal of the present investigation was to determine whether MXE produces PCP-like effects in Sprague-Dawley rats using the PPI paradigm and the behavioral pattern monitor (BPM), which enables analyses of patterns of locomotor activity and investigatory behavior. PPI studies were conducted with several other uncompetitive NMDAR antagonists that produce dissociative effects in humans, including PCP, the S-(+) and R-(-) isomers of ketamine, and N-allylnormetazocine (NANM; SKF-10,047). RESULTS:MXE disrupted PPI when administered at 3 and 10 mg/kg SC. The rank order of potency of MXE and the other test compounds in the PPI paradigm (PCP > MXE > S-(+)-ketamine > NANM > R-(-)-ketamine) parallels their affinities for the PCP binding site reported in the literature. When tested in the BPM, 10 mg/kg MXE induced locomotor hyperactivity, reduced the number of rearings, increased the roughness of locomotor paths, and produced perseverative patterns of locomotion. Administration of PCP (2.25 and 6.75 mg/kg, SC) produced a similar profile of effects in the BPM. CONCLUSIONS: These results indicate that MXE produces a behavioral profile similar to that of other psychotomimetic uncompetitive NMDAR antagonists. Our findings support the classification of MXE as a dissociative drug and suggest that it likely has effects and abuse potential similar to that of PCP and ketamine.
Authors: Jason Wallach; Tristan Colestock; Julià Agramunt; Matt D B Claydon; Michael Dybek; Nadine Filemban; Muhammad Chatha; Adam L Halberstadt; Simon D Brandt; David Lodge; Zuner A Bortolotto; Adeboye Adejare Journal: Eur J Pharmacol Date: 2019-05-29 Impact factor: 4.432
Authors: Michael D Berquist; William S Hyatt; Jonathan Bauer-Erickson; Brenda M Gannon; Andrew P Norwood; William E Fantegrossi Journal: Neuropharmacology Date: 2017-08-19 Impact factor: 5.250
Authors: Arvie Abiero; Chrislean Jun Botanas; Raly James Custodio; Leandro Val Sayson; Mikyung Kim; Hyun Jun Lee; Hee Jin Kim; Kun Won Lee; Youngdo Jeong; Joung-Wook Seo; In Soo Ryu; Yong Sup Lee; Jae Hoon Cheong Journal: Psychopharmacology (Berl) Date: 2019-12-11 Impact factor: 4.530
Authors: In Soo Ryu; Oc-Hee Kim; Young Eun Lee; Ji Sun Kim; Zhan-Hui Li; Tae Wan Kim; Ri-Na Lim; Young Ju Lee; Jae Hoon Cheong; Hee Jin Kim; Yong Sup Lee; Scott C Steffensen; Bong Hyo Lee; Joung-Wook Seo; Eun Young Jang Journal: Int J Mol Sci Date: 2020-06-29 Impact factor: 5.923
Authors: Jason Wallach; Heather Kang; Tristan Colestock; Hamilton Morris; Zuner A Bortolotto; Graham L Collingridge; David Lodge; Adam L Halberstadt; Simon D Brandt; Adeboye Adejare Journal: PLoS One Date: 2016-06-17 Impact factor: 3.240